Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

INB 9 – Oral statement by Knowledge Ecology International

On Monday, 18 March 2024, Knowledge Ecology International (KEI) delivered the following oral statement (in person) at the 9th meeting of the World Health Organization’s (WHO) Intergovernmental Negotiating Body (INB). With respect to Article 11.2, the current references to “to… Continue Reading

Request for Amendment to add Risdiplam for Spinal Muscular Atrophy (SMA) to Schedule 1 of the Canadian Patent Act

On March 1st, Knowledge Ecology International sent a letter to The Hon. Mark Holland, Ministry of Health, and The Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry, urging the prompt consideration of adding risdiplam, a drug to treat spinal… Continue Reading

KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics

Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading

Save the Date – 21 February 2024– EU and US state practice in the Covid-19 response: National law and policy improvements and their relevance to WHO Pandemic Treaty negotiations

Knowledge Ecology International (KEI) invites delegates attending the 8th meeting of the WHO Intergovernmental Negotiating Body (INB) to a side event on Wednesday, 21 February 2024. This event is hybrid. For registration, please contact thiru [at] keionline.org. Title: EU and… Continue Reading

KEI Comment to NIST on the Bayh-Dole Letter to the Washington Post and the Legislative History of the Act

KEI submitted comments to the National Institute of Standards and Technology (NIST) issued a Request for Information regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593) regarding the 2002 Bob Dole and Birch… Continue Reading